Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TuoJie Biotech (Shanghai) KHK compound 14
- Development stage
- Unknown
- Lead developer
- Tuojie Biotech
01
Overview
TuoJie Biotech (Shanghai) KHK compound 14: sourced facts only. name: "Among them, compound 14 exhibited more potent activity than PF-06835919 based on the rat KHK inhibition assay in vivo, and higher drug distribution concentration in the liver." [PMID:37766386]; target: "Among them, compound 14 exhibited more potent activity than PF-06835919 based on the rat KHK inhibition assay in vivo, and higher drug distribution concentration in the liver." [PMID:37766386]; developer: "TuoJie Biotech (Shanghai) Co., Ltd., Shanghai 201206, P. R. China." [PMID:37766386]
02
Targets
KHK (Ketohexokinase)
Beyond the preview
Go deeper on TuoJie Biotech (Shanghai) KHK compound 14.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TuoJie Biotech (Shanghai) KHK compound 14.